Consultant in Allergy, Brigham and Women's Hospital; Clinical Instructor in Medicine, Harvard Medical School, Boston, MA, USA.
Expert Rev Pharmacoecon Outcomes Res. 2008 Jun;8(3):233-41. doi: 10.1586/14737167.8.3.233.
Levocetirizine, a recent, second-generation oral antihistamine, was approved by the US FDA in May 2007 to treat symptoms of allergic rhinitis and chronic idiopathic urticaria.
To review the economic literature for levocetirizine.
Two reviewers conducted a systematic review of the literature to identify abstracts that met the inclusion criteria. Abstracts that were considered acceptable were retrieved with full text for further assessment.
A total of 82 potential studies were identified. After reviewing abstracts, 11 articles were preselected for potential inclusion. Of the 11 full-text articles, three articles met the inclusion criteria.
The pharmacoeconomic literature for levocetirizine was limited. The findings were consistent across the literature, suggesting levocetirizine improved outcomes, leading to incremental cost savings and cost-effectiveness. Since many of the available levocetirizine data come from European studies, differences in practice patterns and medical resources should be considered when extrapolating data to a US clinical setting.
左西替利嗪是一种新型第二代口服抗组胺药，于 2007 年 5 月获得美国食品和药物管理局（FDA）批准，用于治疗过敏性鼻炎和慢性特发性荨麻疹的症状。
综述左西替利嗪的经济学文献。
两位评价者系统地检索文献，以确定符合纳入标准的摘要。对被认为可以接受的摘要进行全文检索，以进一步评估。
共确定了 82 项潜在的研究。在对摘要进行审查后，有 11 篇文章被预先选定为可能的纳入对象。在 11 篇全文文章中，有 3 篇符合纳入标准。
左西替利嗪的药物经济学文献有限。文献中的研究结果一致，表明左西替利嗪改善了结果，导致增量成本节约和成本效益。由于许多现有的左西替利嗪数据来自欧洲的研究，因此在将数据外推到美国临床环境时，应考虑实践模式和医疗资源的差异。
